Skip to main content
Premium Trial:

Request an Annual Quote

Genomic Health Creates Clinical Genetics Subsidiary Called InVitae

NEW YORK (GenomeWeb News) – Genomic Health has established a wholly owned subsidiary focused on providing clinical genetic services to doctors and patients.

In its Form 10-K dated March 14 and filed with the US Securities and Exchange Commission, the Redwood City, Calif.-based firm said the subsidiary, created earlier this month, is called InVitae and will begin offering services in 2013.

"The new subsidiary is expected to focus on accelerating the integration of the human genome into medical practice with an emphasis on bioinformatics and clinical utility beyond our core business of oncology," Genomic Health said in its document. Services and programs offered may include targeted genetic test panels, whole genome sequencing, and information management services.

The services would be provided by physicians "as a component of patient management," the firm added.

Genomic Health first announced the creation of the subsidiary last month in conjunction with its fourth-quarter financial results. Randy Scott is InVitae's CEO and he remains a board member of Genomic Health.

"Investments we have made over the past several years in the development of a robust next-generation sequencing platform and the capabilities we have established in building a successful cancer genomic business make this the ideal time for Genomic Health to expand into both common and rare genetic conditions," Scott said on a conference call last month.

InVitae will offer services not products, but Genomic Health President and CEO Kim Popovits said on the call that it is not a CLIA laboratory.

The company has said it plans to invest up to $20 million into InVitae during the next two years.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.